Business Context and Reporting Period
Company: Collegium Pharmaceutical, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: January 10, 2018
Event Date: January 9, 2018
Context: The Company consummated transactions under a previously disclosed Commercialization Agreement with Collegium NF, LLC and Depomed, Inc. Concurrently, the Company entered into a new financing arrangement with Silicon Valley Bank (SVB) to support these transactions.
Key Financial Metrics and Agreements
Debt and Liquidity:
- New Term Loan: $11,500,000 principal amount from SVB, replacing the existing term loan.
- Interest Rate: Prime rate + 0.75% per annum.
- Repayment Terms: Monthly principal and interest installments commence July 1, 2019. If EBITDA exceeds $2,500,000 for two consecutive quarters prior to June 30, 2019, payments commence January 1, 2020.
- Maturity Date: December 1, 2022.
- Prepayment Fees: 3.0% (Year 1), 2.0% (Year 2), 1.0% (Year 3+), plus a final payment fee of $718,750.
- Letter of Credit: SVB consented to a standby letter of credit in the aggregate amount of $33,750,000.
- Covenants: The Company must maintain a liquidity ratio of at least 2.0 to 1.0.
- Default Penalty: Additional interest of 5.0% per annum applies during an event of default.
Revenue, Profit, and Cash Flow: The filing text does not provide specific values for revenue, profit, cash flow, or margins for the reporting period.
Material Changes
The primary material change is the restructuring of the Company's debt facility and the closing of the Commercialization Agreement. The new loan proceeds are designated to finance payment obligations under the Commercialization Agreement and to repay the balance of the existing term loan.
Outlook, Risks, and Management Commentary
Management Commentary: The Company issued a press release on January 10, 2018, announcing the closing of the Commercialization Agreement. The new financing structure includes a performance-based deferral of principal payments contingent on achieving specific EBITDA thresholds.
Risks and Contingencies:
- Liquidity Covenant Risk: Failure to maintain a 2.0 to 1.0 liquidity ratio constitutes a default.
- Default Consequences: Events of default trigger an additional 5.0% per annum interest rate.
- Prepayment Costs: Significant fees apply if the Company chooses to prepay the loan prior to maturity.
Investor Verification Checklist
- Verify the exact terms of the Commercialization Agreement with Depomed, Inc. to understand the payment obligations funded by the new loan.
- Confirm the Company's current liquidity position to ensure compliance with the 2.0 to 1.0 liquidity ratio covenant.
- Review the definition of EBITDA in the Consent and Amendment to assess the feasibility of deferring loan payments until January 2020.
- Examine the full text of the Consent and Sixth Amendment to Loan and Security Agreement (Exhibit 10.1) for additional covenants or restrictions.